ICAD Icad Dashboard

iCAD Inc., headquartered in Nashua, New Hampshire, is a medical-device manufacturer. iCAD makes cancer detection and radiation therapy devices. iCAD offers computer aided detection and workflow solutions to support detection of breast, prostate and colorectal cancers.

Company profile

Ticker

ICAD

Exchange

NASDAQ

Website

www.icadmed.com

CEO

Michael S. Klein

Incorporated

Delaware

Location

New Hampshire

Fiscal year end

Dec 31

Sector

Manufacturing > Small Arms, Ordnance, and Ordnance Accessories Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Boston Scientific • Baxter International • Stryker • Becton, Dickinson And • Teleflex • Resmed • Hill-Rom • Nuvasive • Integra Lifesciences ...

Former names

HOWTEK INC

SEC CIK

0000749660

Corporate docs

Articles of Incorporation & Bylaws

IRS number

20377419

ICAD stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

iCAD Signs Global Distribution Agreement With Sectra; Terms Not Disclosed

8 Jun 21

iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it has signed a worldwide distribution agreement with Sectra, an

Press releases

Pro users get this 30m faster

iCAD to Participate in the Guggenheim MedTech Disruptors Summit

2 Aug 21

NASHUA, N.H., Aug. 02, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and

iCAD to Report Second Quarter 2021 Financial Results on Thursday, August 5

22 Jul 21

NASHUA, N.H., July 22, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial

iCAD Announces Educational Webinar Featuring Leading Global Experts Discussing New Multidisciplinary Approach for Treating Brain Tumors, May 25

17 May 21

NASHUA, N.H., May 17, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced a virtual roundtable discussion

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

4 May 21

3 Aug 21

31 Dec 21

Financial summary

Financial statements Chart ICAD financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Icad earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	46.91M	46.91M	46.91M	46.91M	46.91M	46.91M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	547.67K	619.08K	1.19M	761K
Cash used (since last report)	n/a	n/a	2.26M	2.56M	4.91M	3.15M
Cash remaining	n/a	n/a	44.64M	44.35M	42M	43.76M
Runway (months of cash)	n/a	n/a	81.5	71.6	35.4	57.5

Beta Read what these cash burn values mean

Recent insider trades

ICAD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Jul 21	Klein Michael S	Employee Stock Option Common Stock	Grant	Aquire A	No	No	17.55	80,000	1.4M	80,000
15 Jul 21	Klein Michael S	Employee Stock Option Common Stock	Grant	Aquire A	No	No	18	55,000	990K	55,000
15 Jul 21	Go Jonathan	Employee Stock Option Common Stock	Grant	Aquire A	No	No	18	19,000	342K	19,000
15 Jul 21	Stevens Stacey M	Employee Stock Option Common Stock	Grant	Aquire A	No	No	18	25,500	459K	25,500
1 Jul 21	Stevens Stacey M	Common Stock	Sell	Dispose S	No	Yes	17.63	5,000	88.15K	137,621
21 Jun 21	Stevens Stacey M	Common Stock	Sell	Dispose S	No	Yes	18.02	8,333	150.16K	142,621
21 Jun 21	Stevens Stacey M	Common Stock	Option exercise	Aquire M	No	No	4.38	8,333	36.5K	150,954
21 Jun 21	Stevens Stacey M	Common Stock	Sell	Dispose S	No	Yes	18.34	236	4.33K	142,621
21 Jun 21	Stevens Stacey M	Common Stock	Option exercise	Aquire M	No	No	6.68	235	1.57K	142,857
21 Jun 21	Stevens Stacey M	Common Stock	Sell	Dispose S	No	Yes	18.02	6,476	116.7K	142,622

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

ICAD institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

49.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	86	81	+6.2%
Opened positions	14	8	+75.0%
Closed positions	9	6	+50.0%
Increased positions	27	29	-6.9%
Reduced positions	31	35	-11.4%

13F shares	Current	Prev Q	Change
Total value	365.85M	664.35M	-44.9%
Total shares	12.32M	10.77M	+14.4%
Total puts	0	0
Total calls	142.1K	85.5K	+66.2%
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
BLK Blackrock	1.4M	$29.76M	-3.4%
Vanguard	1.14M	$24.21M	+6.2%
Granahan Investment Management	928.01K	$19.69M	NEW
Portolan Capital Management	892.01K	$18.93M	-23.2%
G2 Investment Partners Management	746.51K	$15.84M	-15.7%
FHI Federated Hermes	707.05K	$15M	+8.9%
Parkman Healthcare Partners	648.13K	$13.75M	+19.4%
Wellington Management	429.6K	$9.12M	-5.9%
Pura Vida Investments	388.19K	$8.24M	NEW
Geode Capital Management	343.12K	$7.28M	+10.3%

Largest transactions	Shares	Bought/sold	Change
Granahan Investment Management	928.01K	+928.01K	NEW
Pura Vida Investments	388.19K	+388.19K	NEW
Portolan Capital Management	892.01K	-269.19K	-23.2%
Calamos Advisors	230.43K	+230.43K	NEW
Driehaus Capital Management	150K	+150K	NEW
G2 Investment Partners Management	746.51K	-138.86K	-15.7%
Flagship Harbor Advisors	112.18K	+112.18K	NEW
Parkman Healthcare Partners	648.13K	+105.53K	+19.4%
GS Goldman Sachs	110.6K	+95.62K	+638.3%
CVI	83.5K	+83.5K	NEW

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Varian Medical Systems • Hologic • Sensus Healthcare

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: acknowledged, agreed, alleged, balloon, Carter, Consulting, contemplated, deemed, disciplined, efficacy, Entity, Escrowed, exacerbate, faith, franchise, furloughed, furnished, Guggenheim, hereto, higher, immaterial, individual, multiple, nonmelanoma, preferred, reclassification, reinstated, release, released, royalty, scope, sharesthat, thereof, unaware, underwent, vaccinating, vaccine, wave, whe, wrongdoing

Removed: accrual, affecting, Agency, Answer, argument, asserted, asserting, assure, Brachytherapy, breach, breached, CADx, Canadian, category, compliant, continuation, copyright, CRA, differentiated, disrupted, dissolved, Electronic, enrichment, entirety, evaluate, excluding, failure, filing, grow, Harbor, hardware, Hologic, infringement, interference, international, July, meeting, misappropriation, monetary, Motion, October, OEM, offer, Opposition, oral, order, ordering, proxy, pursue, replead, Safe, satisfy, scenario, strategic, submitted, subsidiary, target, tied, typical, unjust, volume, world

From filing 10-Q 2021 Q1